Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients

Infect Dis (Lond). 2019 Aug;51(8):615-617. doi: 10.1080/23744235.2019.1609078. Epub 2019 May 12.

Authors

Stefano Nicolè¹, Massimiliano Lanzafame², Emanuela Lattuada¹, Dora Luise¹, Marta Vecchi¹, Evelina Tacconelli¹, Sandro Vento³

Affiliations

¹ a Infectious Diseases Unit, Policlinico G.B. Rossi , University Hospital , Verona , Italy.
² b Unit of "Diagnosis and Therapy of HIV Infection" , Infectious Diseases Unit, G.B. Rossi University Hospital , Verona , Italy.
³ c Faculty of Medicine , University of Puthisastra , Phnom Penh , Cambodia.

PMID: 31081419
DOI: 10.1080/23744235.2019.1609078

No abstract available

Publication types

Letter
Comment

MeSH terms

Alkynes
Benzoxazines
Cyclopropanes
HIV Infections*
HIV-1*
Humans
Lipids
Sweden

Substances

Alkynes
Benzoxazines
Cyclopropanes
Lipids
efavirenz